Traverse 2024 Testosterone. Testosterone replacement therapy and cardiovascular risk: Khera begins by reviewing the history of the traverse trial and its initial results regarding the impact of testosterone therapy on cardiovascular health.


Traverse 2024 Testosterone

A subtrial of the phase 4 traverse trial revealed testosterone treatment was not associated with a reduction in the incidence of clinical fractures, compared with. The results, from the phase 4 traverse study, showed a negligible difference in cv events among men aged 45 to 80 years with hypogonadism who were treated with testosterone (7%) and those.

Traverse 2024 Testosterone Images References :